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Adjuvant gemcitabine after surgical removal of aggressive
malignant mammary tumours in dogs
Abstract
Canine mammary tumours are generally treated with surgery alone, despite the fact that 50% of them
are malignant and many will eventually lead to recurrence or metastases. A prospective clinical trial in
which dogs with aggressive mammary carcinoma of clinical stages IV and V were treated with surgical
excision (n = 9) or with surgery and adjuvant weekly gemcitabine (n = 10) for at least four cycles was
conducted. Gemcitabine was given as an intravenous infusion at the dose of 800 mg m−2. Aim of the
study was to explore potential beneficial effects of gemcitabine on time to local recurrence (TTR), time
to distant metastases (TTM) and overall survival (OS) in canine patients with operated mammary
tumours bearing high risk for locoregional failure and distant metastases. Also, factors associated with
OS, including neutering status, body weight, age, clinical stage at presentation, tumour size, histological
grade and, in dogs receiving chemotherapy, the number of gemcitabine treatments, were investigated.
Finally, acute toxicities related to chemotherapy and quality of life were assessed in dogs receiving
gemcitabine. Dogs treated with surgery alone or surgery followed by gemcitabine had no difference in
TTR, TTM or OS (P > 0.05). In the group of dogs receiving adjuvant chemotherapy, the number of
gemcitabine treatments was positively correlated with OS (P = 0.017). Gemcitabine treatment was well
tolerated, with no dogs experiencing clinically relevant haematological or gastrointestinal toxicity.
Despite being safe at the present dose, gemcitabine chemotherapy as an adjunct treatment to surgical
excision may not be recommended in dogs with aggressive mammary carcinoma
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Abstract 
Canine mammary tumors are generally treated with surgery alone, despite 50% of them 
are malignant and many will eventually lead to recurrence or metastases. A prospective 
clinical trial in which dogs with aggressive mammary carcinoma of clinical stages IV 
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and V were treated with surgical excision (n=9) or with surgery and adjuvant weekly 
gemcitabine (n=10) for at least 4 cycles was conducted. Gemcitabine was given as an 
intravenous infusion at the dose of 800 mg/m2. Aim of the study was to explore 
potential beneficial effects of gemcitabine on time to local recurrence (TTR), time to 
distant metastases (TTM), and overall survival (OS) in canine patients with operated 
mammary tumors bearing high-risk for locoregional failure and distant metastases. 
Also, factors associated with OS, including neutering status, body weight, age, clinical 
stage at presentation, tumor size, histological grade and, in dogs receiving 
chemotherapy, the number of gemcitabine treatments, were investigated. Finally, acute 
toxicities related to chemotherapy and quality of life were assessed in dogs receiving 
gemcitabine. Dogs treated with surgery alone or surgery followed by gemcitabine had 
no difference in TTR, TTM or OS (p>0.05). In the group of dogs receiving adjuvant 
chemotherapy, the number of gemcitabine treatments was positively correlated with OS 
(p=0.017). Gemcitabine treatment was well tolerated with no dogs experiencing 
clinically relevant hematologic or gastrointestinal toxicity. Despite safe at the present 
dose, gemcitabine chemotherapy as an adjunct treatment to surgical excision may have 
limited beneficial effects in dogs with aggressive mammary carcinoma. 
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Introduction 
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Mammary gland carcinomas are a very common malignancy in adult bitches.1 In dogs, 
approximately 50% of mammary gland tumors are malignant, and 50% of these tend to 
infiltrate the surrounding tissues and metastasize to regional lymph nodes and lungs.1,2 
Furthermore, different histological subtypes can be frequently found in different 
mammary glands, some of which correlate with clinical behavior.1,3 Surgical excision is 
the main treatment option for mammary gland tumors;1,3 however, aggressive tumors 
are rarely cured by surgery alone, and affected dogs may ultimately die or be euthanized 
because of distant metastases.4-6 Due to the poor outcome in many dogs, adjuvant 
treatments are clearly warranted. Chemotherapy has been rarely attempted in dogs with 
aggressive malignant mammary tumors and scarce data has been published on post-
operative adjuvant treatments.7,8 At present, a standard of care for adjuvant 
chemotherapy has not been established. 
In human patients with breast cancer, mastectomy alone is often disappointing. Thus, 
adjuvant systemic therapy following local treatment is used in order to eradicate 
micrometastases and ameliorate disease-free interval and overall survival.9 Currently, 
adjuvant chemotherapy is offered to patients with node-positive tumors or with high-
grade tumors and to those with metastatic disease.10-12 Chemotherapeutic drugs that 
have shown efficacy in the management of breast cancer include anthracyclines (such as 
doxorubicin or epirubicin),13-16 taxanes (such as paclitaxel or docetaxel),17-19 and the 
newly introduced vinorelbine,20 capecitabine,20,21 and gemcitabine22-25 in both pretreated 
and unpretreated patients, either as single agents or in combination regimens. In 
particular, gemcitabine, a pyrimidine nucleoside antimetabolite, has emerged as one of 
the most promising new cytotoxic agents, because of its proven antitumor activity in a 
variety of solid tumors, its good toxicity profile and no apparent multidrug resistance.26 
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Gemcitabine is not widely used in veterinary medicine, and few articles are available in 
the literature.27-31 To the authors’ knowledge, adjuvant gemcitabine chemotherapy for 
resected mammary cancer care has not been documented in dogs. The aims of the study 
were i) to verify the potential beneficial effects of gemcitabine and surgery over surgery 
alone on time to local recurrence (TTR), time to distant metastases (TTM) and overall 
survival (OS) in dogs with mammary carcinoma; ii) to assess factors contributing to OS 
in either group of dogs; and iii) to assess the safety of gemcitabine administration and 
quality of life in dogs receiving adjuvant chemotherapy. 
 
 
Materials and methods 
 
Patient eligibility 
Following radical unilateral or bilateral mastectomy, depending on tumor distribution in 
the mammary chains, canine patients were eligible for recruitment only if they had 
selected malignant histological variants, including simple carcinoma, squamous cell 
carcinoma, sarcoma and carcinosarcoma with infiltrative growth in the stroma and 
residual neoplastic cells at the primary surgical site. Inflammatory mammary carcinoma 
was excluded. In addition, to be included in the study, dogs with mammary tumors had 
to exhibit one or more of the listed features: (1) vascular and/or lymphatic invasion, (2) 
metastases to regional lymph nodes, and (3) distant metastases. In cases of multiple 
mammary tumors, the most malignant tumor was considered. All dogs were staged 
accordingly to the WHO clinical staging system for canine mammary tumors.1 For dogs 
undergoing chemotherapy, additional entry requirements included fully informed, 
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written consent from the pet owner, the presence of adequate bone marrow function, as 
evidenced by neutrophil counts of ≥3.000/μl, platelet counts of ≥120.000/μl, and packed 
cell volume ≥30%, and administration of at least 4 doses of gemcitabine. Dogs were 
enrolled irrespective of hormone receptor status. Dogs affected by coexistent non-
mammary malignancies, and those which had received previous chemotherapy or 
hormonal therapy were not enrolled. 
Post-operative chemotherapy was offered to all dogs. If owners rejected adjuvant 
treatment, dogs were included in Group 1. Dogs whose owners wished to pursue 
chemotherapy were included in Group 2. 
 
Pre-treatment evaluation 
Before entering the study, all patients underwent staging work-up including a complete 
history and physical examination, bidimensional measurement of the tumors, cytologic 
evaluation of the mammary tumor and of regional lymph nodes, complete blood cell 
count (CBC), serum biochemical profile, urinalysis, abdominal ultrasound, and thoracic 
radiographs (right and left lateral, and ventrodorsal views). 
Radical unilateral mastectomy was performed if only one mammary chain was 
involved, and bilateral mastectomy if either mammary chain was involved. For staging 
purposes, regional lymphadenectomy was performed in all dogs. 
 
Histological assessment 
Tissue samples were routinely fixed in 10% neutral buffered formalin and embedded in 
paraffin. Five-micron sections were taken, stained with hematoxylin and eosin (H&E) 
and examined by ligth microscopy. Histological assessment of mammary tumors and 
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draining lymph nodes was performed by two independent pathologists (FA, AR) 
according to the World Health Organization’s (WHO) classification scheme32. The 
following data were recorded: histological diagnosis, status of the resection margins, 
presence of stromal infiltration, vascular-lymphatic invasion, and grade of the tumor 
determined on the basis of previously described guidelines.5 Hormone receptor status 
was not evaluated. 
 
Post-operative chemotherapy plan 
Patients were scheduled to start chemotherapy one week after mastectomy. Gemcitabine 
(Gemzar, Eli Lilly and Company, Sesto Fiorentino, Firenze, Italy) was administered 
intravenously (IV) at a dose of 800 mg/m2 once weekly for at least 4 cycles. The dose 
used in this study was derived from a phase I clinical trial in 33 dogs with transitional 
cell carcinoma of the urinary bladder33. After reconstitution of one 200 mg gemcitabine 
vial with 5 ml of 0.9% sodium chloride, a concentration of 38 mg/ml was obtained. 
Reconstituted gemcitabine was then added to a 100 ml 0.9% saline bag and 
administered over a period of 30 to 60 minutes via an indwelling catheter through a 
peripheral vein. 
Chemotherapy was prepared within a class II biologic safety cabinet (Cytosafe-N 2003, 
Faster, Ferrara, Italy). To reduce occupational exposure, chemotherapy was 
administered by safe handling techniques and personal protection equipment. After 
chemotherapy administration, all used materials were disposed in special boxes 
accordingly to safety guidelines. 
All patients were given prophylactic 25 mg kg-1 BID oral clavulanate-potentiated 
amoxicillinc (Synulox tablets 500 mg, Pfizer, Rome, Italy) for 7 days after each of the 
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first 3 treatments, and only if needed thereafter. Standard antiemetic therapy with SQ 
0.4 mg kg-1 metoclopramide (Plasil tablets 10 mg, Lepetit, Milan, Italy) was 
administered if necessary. Additional experimental drugs were not administered during 
the study. 
During the chemotherapeutic period, dogs were seen weekly as outpatients for clinical 
assessment, to record adverse events and toxicities as reported by the owner, to measure 
hematological and, when indicated, biochemical parameters, and finally to administer 
gemcitabine. Furthermore, thorax radiographs were obtained after 2 and 4 gemcitabine 
treatments, based on the presence or absence of lung metastases at presentation, 
respectively. Thoracic radiographs were also obtained at the end of treatment in all 
patients. Chemotherapy was suspended if intolerable toxicity occurred or beneficial 
effects were not evident on local recurrence or distant metastases. Additional 
gemcitabine administrations, up to a maximum of 10, were administered to patients 
exhibiting complete remission or, in cases of pulmonary metastases, if respiratory 
symptoms had improved. Toxicity resulting from gemcitabine was assessed based on 
the dog history, physical examination and CBC before the beginning of each next cycle, 
as stated by the Veterinary Co-operative Oncology Group34. If treatment had to be 
delayed, the CBC was repeated every 2 days in order to resume chemotherapy as soon 
as possible. A new cycle at full dose was only started if neutrophils were >3.000/μl, 
platelet count was >120.000/μl, and the non-hematologic toxicity grade was ≤1. Dose-
limiting toxicity was defined as grade 3 or 4 hematologic or gastrointestinal toxicity. 
The safety analysis was performed on data from all patients who received gemcitabine. 
 
Follow-up 
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After surgical excision (Group 1) or completion of chemotherapy (Group 2), dogs were 
scheduled to be checked once monthly for three months, and every three months 
thereafter. Follow-up examination included physical examination with particular 
attention to local recurrence, CBC, serum biochemical profile, abdominal ultrasound, 
and thoracic radiographs (three views). 
 
Statistical analysis 
Data analysis was performed with GraphPad Prism version 4.0 (GraphPad Software, 
San Diego, CA). For both groups, survival time, TTM (beyond regional lymph nodes), 
and TTR were explored with the Kaplan-Meier product limit method followed by 
logrank test. In either group, timing was considered from surgical excision. In the 
analysis of survival, distant metastasis and local recurrence, dogs were censored if they 
were alive at the time of data accrual closure. For time to distant metastases and local 
recurrence dogs were also censored if, by the last examination, distant metastases had 
not developed or the tumor had not reappeared locally, respectively. In the two groups, 
the following variables were evaluated for their influence on survival time: neutering 
status, body weight, age, clinical stage at presentation, tumor size at surgery (measured 
at its maximum diameter), histological grade and, in dogs receiving chemotherapy, the 
number of gemcitabine treatments. Correlations were not investigated for TTM and 
TTR because of the low number of dogs which developed metastasis or local recurrence 
available for analysis. Spearman’s correlation coefficient was used to measure the 
strength of relationships. Significance was set at a p value of ≤0.05. 
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Results 
 
Patient characteristics 
Nineteen dogs with histologically confirmed malignant mammary gland tumors were 
enrolled. Among these, 9 dogs were treated with surgery alone (Group 1), whereas the 
remaining 10 received post-operative adjuvant gemcitabine (Group 2). All patients were 
treated at the Clinica Veterinaria L’Arca between October 2003 and October 2006. 
In Group 1, 6 breeds were represented, including crossbreeds (n=4), and one each of the 
following: shi-tzu, German shepherd, German pointer, poodle, and Yorkshire terrier. 
Median age at presentation was 12 years (range, 8-15), and median body weight was 
18.2 kg (range, 4.2-34.3). Six dogs (66.7%) were intact females, and the remaining 3 
had been spayed at the ages of 10, 11 and 13 years, respectively. Unilateral radical 
mastectomy was performed in 3 dogs (33.3%); whereas bilateral mastectomy was 
performed in the remaining 6 dogs (66.7%), and 4 out of the 6 intact bitches were 
ovariohysterectomized at the time of surgery. 
In Group 2, 7 breeds of dogs were represented. Mixed dogs were the most common 
(n=4; 40%), followed by one each of the following: Yorkshire terrier, beagle, German 
shepherd, shi-tzu, English setter and White West Highland terrier. Median age at 
diagnosis was 10 years (range, 8-15), and median body weight was 15 kg (range, 4.75-
34.95). Five dogs (50%) were intact females and 5 dogs were spayed. All dogs had been 
spayed between the age of 9 and 15 years. Unilateral radical mastectomy was performed 
in 6 dogs (60%), whereas surgery consisted in bilateral mastectomy in the remaining 4 
bitches (40%). The 5 intact dogs were ovariohysterectomized at the time of surgery.  
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Tumor characteristics 
Group 1 
At presentation, the median number of tumors per dog was 3 (range, 1-6) and the 
median size of the major tumor nodule at its maximum diameter was 4.2 cm (range, 0.9-
20). When histological type was considered, all dogs but one (88.9%) had simple 
carcinoma, 3 of which were tubulopapillary, 2 were tubular, 2 were anaplastic and 1 
was solid. One dog (11.1%) had a carcinosarcoma. The tumors were also graded 
according to the degree of stromal infiltration, vascular-lymphatic invasion and distant 
metastases, as follows: 8 (88.9%) tumors were grade 2, and one (11.1%) was classified 
as grade 3. Residual neoplastic cells were noticed at the primary surgical site in all dogs. 
According to WHO clinical staging system for canine mammary tumors, 7 (77.8%) of 
the bitches had stage IV disease and 2 (22.2%) had stage V. The distant metastatic site 
for both dogs with stage V disease was the lungs. Eight dogs (88.9%) had regional 
lymph node involvement; of these, 7 were inguinal and 1 was axillary. Overall, all 9 
bitches had metastatic disease at presentation, and 2 of these had pulmonary 
involvement. 
Group 2 
In this group, the median number of tumors per dog was 2 (range, 1-6) and the median 
size of the major tumor nodule at its maximum diameter was 3.7 cm (range, 1.7-6). 
Concerning histological type, 8 bitches (80%) had simple carcinoma, 3 of which were 
anaplastic, 2 were solid, 2 were tubulopapillary and one was tubular. In addition, there 
was one carcinosarcoma and one adenosquamous carcinoma. The tumors were 
histologically graded as follows: 6 tumors (60%) were grade 2, and 4 tumors (40%) 
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were grade 3. Histologic evidence of residual tumor at the primary surgical site was 
noted in all dogs. 
At diagnosis, 6 dogs (60%) had stage IV disease and 4 (40%) had stage V. The 
metastatic site in the dogs with stage V disease was the lungs, whereas the histologically 
involved lymph nodes were the inguinal in 7 dogs, the axillary in one dog, and both, the 
inguinal and the axillary, in one dog. Overall, all 10 dogs had metastatic disease at the 
beginning of gemcitabine chemotherapy, and 4 of these had pulmonary involvement. 
 
Chemotherapy 
Chemotherapy was started between 7 and 14 days after mastectomy in 10 dogs. A total 
of 61 gemcitabine treatments were administered at the dose of 800 mg/m2. Dogs 
received from 4 to 10 gemcitabine treatments (median, 6.1). All patients completed the 
planned four cycles of chemotherapy, and 7 of them (70%) received 1-6 additional 
treatments. 
 
Response and time-to-event measures 
The median follow-up time (from surgery to last visit) was 178 days (range, 17-410) 
and 203 days (range, 52-659) for Group 1 and 2, respectively. 
Overall, 4 (44.4%) out of 9 dogs with no postoperative gemcitabine developed local 
recurrence (Group 1). Median time to local recurrence was 175 days (range, 150-345). 
None of the 10 dogs that received adjuvant chemotherapy developed local recurrence 
(Group 2). Time to local recurrence was not different between groups. 
In Group 1, 4 dogs had distant metastases. In particular, 2 dogs showed pulmonary 
metastases at presentation, and 2 others developed pulmonary metastases after 212 and 
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216 days, respectively. In Group 2, 5 dogs that received gemcitabine had distant 
metastases, 4 of which had pulmonary metastases at presentation with signs of 
respiratory distress, and one developed peritoneal carcinomatosis 52 days after 
beginning of chemotherapy. One of the dogs with lung metastases developed 
histologically confirmed bone metastases to the spine 55 days after beginning of 
chemotherapy. In the 4 dogs with pulmonary involvement and respiratory signs, the 
owners reported improvement of clinical signs after gemcitabine treatment. Moreover, 
in one of these dogs a size reduction of the pulmonary metastases was observed for 40 
days of gemcitabine treatment, as assessed by measurements of tumoral lesions on chest 
films (Fig. 2). However, despite initial amelioration in these 4 dogs, all were eventually 
euthanized due to disease progression, after 55, 70, 195 and 210 days, respectively. 
Time to distant metastases was not different between the two groups. 
At the time of data analysis closure, 8 dogs were still alive, whereas the remaining 11 
had died as a result of their mammary disease. In particular, 6 out of the 9 dogs which 
had not been treated in an adjuvant setting had died by the end of the study period, and 
5 out of 10 dogs died in the group receiving adjuvant gemcitabine. With Kaplan-Meier 
analysis, in Group 1 a median survival time of 212 days was calculated and in Group 2 
median survival was 200 days. The cause of death for animals in Group 1 was local 
recurrence (n=2), and development or progression of pulmonary metastases (n=4). Two 
of the 3 dogs that survived had evidence of local recurrence and the last one had no 
evidence of disease. Among dogs in Group 2, all 5 animals that did not survive had 
distant metastases. The 5 survivors had no evidence of local recurrence or of distant 
metastases, at 172, 405, 415, 656, and 659 days. Furthermore, none of the 5 dogs with 
lymph node metastases at presentation experienced disease progression. OS did not 
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differ between dog treated with surgery alone or with surgery and adjuvant gemcitabine 
(Fig. 1). 
Results of treatments for Group 1 and 2 are summarized in Table 1 and Table 2, 
respectively. 
Regarding factors associated with OS, a significantly positive correlation was 
documented for the number of gemcitabine treatments in dogs receiving adjuvant 
chemotherapy (p=0.017). No correlations were found for other analyzed variables. 
 
Toxicity 
All 10 patients receiving gemcitabine chemotherapy were evaluated for toxicity. 
Treatment was well tolerated and no dose reduction was necessary during the study 
period. No dog required treatment interruption. Most of the treatments (57 of 61, 93%) 
were administered every week, as planned. In 4 cases treatment delays were necessary 
due to grade 1 neutropenia, which resolved uneventfully after 3, 4, 4 and 5 days, 
respectively, by adding oral 5 mg kg-1 SID enrofloxacin (Baytril tablets 150 mg, Bayer, 
Milan, Italy) for one week with no need for hospitalization. All treatment delays 
occurred after the first 4 courses of chemotherapy. Grade 2 to grade 4 hematologic 
toxicity was not reported during the study. 
Non-hematologic toxicity occurred in very rare cases and was limited to grade 1-2 
gastrointestinal adverse events. One dog experienced nausea without alteration in eating 
habits for 24 hours after each cycle, whereas another dog had one episode of loss of 
appetite of 36 hours duration and 3-5 episodes of vomiting in 48 hours. Further non-
hematologic toxicities were not observed during the study. Chemotherapy did not affect 
wound healing in any case. 
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Discussion 
Much interest has focused on the treatment of mammary carcinoma in dogs. Until 
recently, mammary carcinoma in bitches was viewed as a surgical issue and no medical 
treatment was recommended.1,3 However, approximately 50% of mammary tumors 
behave aggressively and will ultimately locally recur and progress to metastatic disease, 
suggesting that occult metastases are already present when dogs first present with 
operable mammary cancer.1,2 As a consequence, surgical excision alone in most 
instances is not curative and, to improve outcome, adjuvant chemotherapy should be 
explored in clinical trials. Adjuvant chemotherapy in dogs that have undergone 
mastectomy may prove effective to treat occult regional or systemic disease (such as 
lymph node or pulmonary micrometastases), palliate evident distant metastases, and 
sterilize tumor margins in case of incomplete surgical excision. 
Recently, the use of adjuvant chemotherapy for the treatment of resected canine 
mammary tumors has been reported.7,8 In an early study, 8 bitches with malignant 
mammary tumors were treated in an adjuvant post-operative setting with 5-fluorouracil 
and cyclophosphamide.7 When compared with bitches treated by surgery alone, the 
authors found a benefit in survival time if chemotherapy was added.7 More recently, 12 
dogs with invasive mammary gland tumors were treated with doxorubicin or docetaxel 
after mastectomy; however, outcome was not improved by chemotherapy.8
In people, gemcitabine has shown activity in a variety of solid tumors,35-39 has limited 
toxicity, and does not exacerbate toxic effects of other chemotherapeutic drugs.40 
Moreover, among the novel chemotherapeutic drugs, gemcitabine has emerged as an 
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important agent in the treatment of breast cancer in women.22,24,26,41-44 The efficacy and 
tolerability of this chemotherapeutic drug, as well as its lack of cross-resistance with 
anthracyclines and taxanes, have led to its inclusion in combination regimens.45-48
Motivated by the favorable results in humans with aggressive breast cancer, and the 
good tolerability shown in canine patients,33 we designed a clinical protocol with 
gemcitabine given as a single agent to dogs with aggressive mammary cancer. In the 
present study, the analysis of post-operative adjuvant therapy with gemcitabine showed 
prolongation of the recurrence-free survival over no adjuvant chemotherapy. In 
particular, none of the dogs receiving adjuvant gemcitabine developed local relapse, 
whereas 4 out of the 9 untreated dogs experienced local recurrence. Although some 
increase in local control rate was observed in this study, no clear advantage in terms of 
TTM and OS was achieved for adjuvant chemotherapy over surgery alone. These results 
may be partly attributable to the presence of clinically evident pulmonary metastases in 
4 out of the 10 treated dogs. According to the Goldie and Coldman model,49 the number 
of resistant tumor cells increases directly with the size of the tumor, thus accounting for 
the possibility of resistant cell lines if widespread macro-metastatic disease is already 
present. Another possible reason is that this study had an insufficient follow-up interval 
such that an OS advantage could not be discerned. In general, the effect of an adjuvant 
therapy should be considered in terms of both disease-free interval and OS, and the 
potential benefits of treatment need to be carefully balanced against its potential side 
effects. We believe that the improvement in disease-free interval achieved in the treated 
dogs may ultimately translate into a survival benefit as well. This consideration is 
supported by the fact that none of the node-positive dogs treated with chemotherapy 
experienced disease progression, suggesting that gemcitabine may have eradicated 
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micrometastases. Of note, one of the dogs with stage V disease experienced a reduction 
in size of lung metastases. As a consequence, it can be assumed that systemic therapy 
given to selected dogs with operable mammary tumors in their early-stage disease may 
further improve the long-term outlook. At present, it is well known that the extent of 
disease and several histopathological features partially reflect the biologic behaviour of 
canine mammary tumors.32,50-53 Hopefully, a more detailed understanding of the 
molecular biology of canine mammary cancer will ultimately lead to the identification 
of the subset of cancer patients who would most benefit from the use of chemotherapy 
in an adjuvant setting. 
Limitations of this study are the low number of recruited patients in both groups, partly 
due to the strict enrolment criteria and the relatively short follow-up achieved in some 
dogs. We hypothesize that the patient number was too low to detect statistical 
differences among groups, and that longer follow-up would be necessary to better 
understand the potential beneficial effects of gemcitabine on survival time and time to 
occurrence of metastases. 
Several clinico-pathological prognostic factors have been identified for canine 
mammary tumors.5,50-53 In the present study, several variables were evaluated for their 
prognostic influence, and the analysis indicated that clinical stage at diagnosis had a 
statistically significant negative influence on the survival rates of dogs treated by 
surgery alone. This finding is in agreement with previously reported data.53,54 The 
number of gemcitabine treatments had a significant positive influence on survival time 
of treated dogs in this study. However, this finding needs to be interpreted with caution, 
as it may be explained by the fact that dogs living longer received additional cycles of 
gemcitabine. None of the other analyzed variables proved to be associated in the present 
 16
canine population, probably due to the low number of enrolled dogs and to the 
aggressive nature of the tumor in the selected animals. 
In this study high-dose gemcitabine treatment was well tolerated with a low incidence 
of adverse events. Quality of life was maintained, if not improved in all treated dogs, 
especially in those presenting with respiratory signs. The planned timing of 
chemotherapy was respected for most of the cycles and only 4 treatments were delayed 
as a result of grade 1 neutropenia. In these 4 dogs, neutropenic episodes were 
uncomplicated and rapidly reversible, and hospitalization was not necessary. It may be 
possible that prophylactic antibiotic therapy given to all dogs during the first 3 weeks of 
treatment prevented infection-related events and attendant chemotherapy delays and 
dose reductions. Moreover, in this study non-hematologic toxicity was very mild and 
was observed in two dogs only. No grade 2-4 hematologic and grade 3-4 non-
hematologic toxicity was observed, and no treatment-related deaths occurred. These 
findings have important implications, not only for the feasibility of gemcitabine in the 
adjuvant setting, but also for its potential use in combination regimens.  
In conclusion, there are still many unanswered questions about the absolute benefit of 
adjuvant chemotherapy in canine mammary tumor care, and further studies are needed 
to better understand the role of gemcitabine and to substantiate its use. In human 
patients, combination regimens are generally superior to single agents in terms of 
response rate, duration of response and survival. Indeed, as single agent, gemcitabine 
yields response rates ranging from 16% to 37%; whereas, if combined with other 
chemotherapeutic drugs, response rates rise to 50% to 80%.40-48 Given these data, future 
veterinary clinical trials in dogs with resected aggressive mammary carcinoma should 
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focus on the adjuvant role of gemcitabine alone or in combination with other 
chemotherapeutic drugs. 
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